10月28日，科创板迎来历史性时刻——武汉禾元生物科技股份有限公司（以下简称"禾元生物"）、西安 奕斯伟材料科技股份有限公司（以下简称"西安奕材"）和广州必贝特医药股份有限公司（以下简称"必 贝特"）等3家未盈利企业鸣锣上市，正式成为科创板科创成长层首批新注册企业。截至当日收盘，上述 3家公司股价较发行价分别上涨213.49%、198.72%和74.41%，以亮眼涨幅稳稳收获"开门红"。 最后，对"创新驱动发展"这一国家战略的坚定认同，构成了第三重信心。当前全球产业链重构加速，半 导体、生物医药等"硬科技"领域的自主可控已成为保障产业链安全、推动经济高质量发展的关键抓手。 此次上市的3家企业，恰好精准卡位这些战略赛道。这种战略契合度，让投资者看到的不仅是单个企业 的盈利潜力，更是"硬科技"赛道的长期价值逻辑。当投资者确信企业成长与国家战略同频、板块发展与 科技叙事同步时，自然愿意用长期资金"投票"，这也成为此次"开门红"背后最深厚的信心底色。 由此可见，科创成长层的"开门红"，不是偶然的市场热度，而是企业硬核创新力、板块制度承载力与国 家战略引领力深度同频的必然结果。未来，当这种"企业敢创新、市场愿支持、战略 ...

Group 1 - The first batch of new registered companies, including Xian Yicai, Heyuan Bio, and Bibete, has been listed on the Sci-Tech Innovation Board, marking a significant step in capital market support for technological innovation and new productivity development [2][4] - On the first day of trading, the three companies experienced substantial gains, with Heyuan Bio and Xian Yicai both rising approximately 200%, and Bibete increasing by 74.41% [3][5] - The listing of these companies reflects a growing enthusiasm among institutional investors, indicating recognition of their long-term investment value, despite warnings about the risks associated with investing in unprofitable companies [5][4] Group 2 - As of October 28, the Sci-Tech Innovation Board has 592 listed companies with a total market capitalization exceeding 9 trillion yuan, showcasing the board's focus on "hard technology" enterprises [6] - Since the implementation of the "1+6" reform policy in June, the Sci-Tech Innovation Board has accepted 26 new companies, including 8 unprofitable ones, with a total IPO financing amount of 16.95 billion yuan, representing a 54% year-on-year increase [7] - The Shanghai Stock Exchange aims to enhance its support for high-quality development by identifying and supporting innovative companies in fields such as artificial intelligence and commercial aerospace, while also improving regulatory effectiveness [8][10]